(Q33574315)

28 July 2017

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer (English)

1 reference

28 July 2017

Naoki Takahashi

1

1 reference

28 July 2017

Yasuhide Yamada

2

1 reference

28 July 2017

Hirokazu Taniguchi

3

1 reference

28 July 2017

Masaru Fukahori

4

1 reference

28 July 2017

Yusuke Sasaki

5

1 reference

28 July 2017

Hirokazu Shoji

6

1 reference

28 July 2017

Yoshitaka Honma

7

1 reference

28 July 2017

Satoru Iwasa

8

1 reference

28 July 2017

Atsuo Takashima

9

1 reference

28 July 2017

Ken Kato

10

1 reference

28 July 2017

Tetsuya Hamaguchi

11

1 reference

28 July 2017

Yasuhiro Shimada

12

1 reference

28 July 2017

29 April 2014

1 reference

28 July 2017

1 reference

28 July 2017

7

1 reference

28 July 2017

271

1 reference

https://scigraph.springernature.com/pub.10.1186/1756-0500-7-271

28 July 2017

0 references

cites work

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

NRAS mutation status is an independent prognostic factor in metastatic melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

28 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

PIK3CA mutation associates with improved outcome in breast cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Mutation of the PIK3CA oncogene in human cancers

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

BRAF mutation in thyroid cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Mutations of PIK3CA in gastric adenocarcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

High frequency of mutations of the PIK3CA gene in human cancers

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

BRAF and KRAS mutations in stomach cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Novel therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

BRAF and RAS mutations in human lung cancer and melanoma

21 January 2018

1 reference

12 December 2020

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

12 December 2020

Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability

1 reference

12 December 2020

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-0500-7-271

1 reference

Dimensions Publication ID

28 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1756-0500-7-271

9 September 2019

1 reference

28 July 2017

1 reference